Several reasons may explain the limitations of targeting mTORC1 in cancer therapy—resistant mutations of mTOR, activation of alternate proliferative signaling pathways, and intratumoral heterogeneity of mTOR activity, among others [22]. The gene discussed is MTOR; the disease is cancer.